Ubiquitin ligase gp78 targets unglycosylated prion protein PrP for ubiquitylation and degradation

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Shao, Jia ^a   Choe, Vitnary ^b   Cheng, Haili ^b   Tsai, Yien Che ^c   Weissman, Allan M ^c   Luo, Shiwen ^a   Rao, Hai ^b  

^a NANCHANG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE GP78; UNCLASSIFIED DRUG; AMFR PROTEIN, HUMAN; AMFR PROTEIN, MOUSE; AUTOCRINE MOTILITY FACTOR RECEPTOR; PRION; UBIQUITIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN QUALITY; PROTEIN TARGETING; QUALITY CONTROL; UBIQUITINATION; ANIMAL; C57BL MOUSE; CHEMISTRY; GLYCOSYLATION; HEK293 CELL LINE; METABOLISM; MOUSE; PRION;

ANIMALS; GLYCOSYLATION; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; PRIONS; PROTEOLYSIS; RECEPTORS, AUTOCRINE MOTILITY FACTOR; UBIQUITIN; UBIQUITINATION;

EID: 84899506914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092290     Document Type: Article

References (26)

1. Finley D, Ulrich HD, Sommer T, Kaiser P (2012) The ubiquitin-proteasome system of Saccharomyces cerevisiae. Genetics 192: 319-360.
2. Metzger MB, Hristova VA, Weissman AM (2012) HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci 125: 531-537.
3. Ciechanover A (2013) Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Bioorg Med Chem 21: 3400-3410.
4. Needham PG, Brodsky JL (2013) How early studies on secreted and membrane protein quality control gave rise to the ER associated degradation (ERAD) pathway: the early history of ERAD. Biochim Biophys Acta 1833: 2447-2457.
5. Stolz A, Wolf DH (2010) Endoplasmic reticulum associated protein degradation: a chaperone assisted journey to hell. Biochim Biophys Acta 1803: 694-705.
6. Dennissen FJ, Kholod N, van Leeuwen FW (2012) The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim? Prog Neurobiol 96: 190-207.
7. Dantuma NP, Lindsten K (2010) Stressing the ubiquitin-proteasome system. Cardiovasc Res 85: 263-271.
8. Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A (2001) Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. Embo J 20: 5383-5391. (Pubitemid 32959458)
9. Ma J, Lindquist S (2001) Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci U S A 98: 14955-14960. (Pubitemid 34013951)
10. Roucou X, Guo Q, Zhang Y, Goodyer CG, LeBlanc AC (2003) Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J Biol Chem 278: 40877-40881. (Pubitemid 37280906)
11. Andre R, Tabrizi SJ (2012) Misfolded PrP and a novel mechanism of proteasome inhibition. Prion 6: 32-36.
12. Lloyd S, Mead S, Collinge J (2011) Genetics of prion disease. Top Curr Chem 305: 1-22.
13. Aguzzi A, Falsig J (2012) Prion propagation, toxicity and degradation. Nat Neurosci 15: 936-939.
14. Ma J (2012) The role of cofactors in prion propagation and infectivity. PLoS Pathog 8: e1002589.
15. Ma J, Lindquist S (2002) Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 298: 1785-1788. (Pubitemid 35404121)
16. Ma J, Wollmann R, Lindquist S (2002) Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298: 1781-1785. (Pubitemid 35404120)
17. Deriziotis P, Andre R, Smith DM, Goold R, Kinghorn KJ, et al. (2011) Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO J 30: 3065-3077.
18. Ermonval M, Mouillet-Richard S, Codogno P, Kellermann O, Botti J (2003) Evolving views in prion glycosylation: functional and pathological implications. Biochimie 85: 33-45. (Pubitemid 36625979)
19. Ashok A, Hegde RS (2008) Retrotranslocation of prion proteins from the endoplasmic reticulum by preventing GPI signal transamidation. Mol Biol Cell 19: 3463-3476.
20. Nunziante M, Ackermann K, Dietrich K, Wolf H, Gadtke L, et al. (2011) Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein. J Biol Chem 286: 33942-33953.
21. Apodaca J, Kim I, Rao H (2006) Cellular tolerance of prion protein PrP in yeast involves proteolysis and the unfolded protein response. Biochem Biophys Res Commun 347: 319-326. (Pubitemid 44015679)
22. Dron M, Dandoy-Dron F, Farooq Salamat MK, Laude H (2009) Proteasome inhibitors promote the sequestration of PrPSc into aggresomes within the cytosol of prion-infected CAD neuronal cells. J Gen Virol 90: 2050-2060.
23. Tsai YC, Leichner GS, Pearce MM, Wilson GL, Wojcikiewicz RJ, et al. (2012) Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol Biol Cell 23: 4484-4494.
24. Aguzzi A, Heikenwalder M (2006) Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol 4: 765-775. (Pubitemid 44420127)
25. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, et al. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871-874. (Pubitemid 37339628)
26. Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, et al. (2007) Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53: 325-335. (Pubitemid 46161264)